Search Results 1011-1020 of 15387 for alt

1. Study of ALN-GO1 in Healthy Adult Subjects and Patients With Primary Hyperoxaluria Type 1 - Mayo Clinic

   Abnormal for AST/ALT and any other clinical safety laboratory result considered clinically significant; Received an investigational agent within 3 months ...

2. An Open-label Study to Investigate the Efficacy, Safety and Tolerability of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy - Mayo Clinic

   Serum alanine aminotransferase (ALT) > 2.5× ULN. Positive pregnancy test. The subject has participated in another clinical study involving an IP or ...

3. Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - Mayo Clinic

   AST and ALT ≤ 3.0 times ULN (unless due to hemolysis or CLL); Willing to provide blood samples; Able to take acetylsalicylic acid (ASA) (81 or 325 mg) daily ...

4. A Phase 2 Study of Anti-PD-L1 Antibody Atezolizumab in Alveolar Soft Part Sarcoma - Mayo Clinic

   ... (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3 x ULN (AST and/or ALT ≤ 5 x ULN for patients with liver involvement). Alkaline phosphatase ≤ 2.5 x ...

5. Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome - Mayo Clinic

   ALT and AST ≤ 2.5 × ULN;; Serum creatinine ≤ 2.0 mg/dL. Willingness to provide consent for bone marrow samples. Bone marrow samples will be required for ...

6. A Study to Assess Dynamic Changes in Plasma Proteome to Identify Early Detection and Treatment Response Biomarkers for HGSOC - Mayo Clinic

   alanine aminotransferase (ALT)/ aspartate aminotransferase (AST)/ alkaline phosphatase < 2 x ULN. Exclusion Criteria: Patients who have received treatment ...

7. Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis

   Participation eligibility · Serum creatinine clearance < 50 ml/min (as calculated by the Cockcroft-Gault formula); · Alanine Aminotransferase (ALT) > 2x the ...

8. A Study of APR-246 and Pembrolizumab in Patients with Solid Tumor Malignancies - Mayo Clinic

   Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 × ULN, unless due to involvement by the underlying malignancy. Age ≥ 18 years at ...

9. A Study to Evaluate RGLS4326 to Treat Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

   Alanine aminotransferase (ALT) < 1.5 x ULN;; Aspartate aminotransferase (AST) < 1.5 x ULN;; Alkaline phosphatase (ALP) < 1.5 x ULN;; Gamma-glutamyl transferase ...

10. A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions - Mayo Clinic

    The participant has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values >1.5 times the upper limit of normal (ULN). 4. Participant has ...